Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.
OBJECTIVE
HIBM (Hereditary Inclusion Body Myopathy) is a recessive hereditary disease characterized by adult-onset, slowly progressive muscle weakness sparing the quadriceps. It is caused by a single missense mutation of each allele of the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene, a bifunctional enzyme catalyzing the first two steps of sialic acid synthesis in mammals. However, the mechanisms and cellular pathways affected by the GNE mutation and causing the muscle weakness could not be identified so far. Based on recent evidence in literature, we investigated a new hypothesis, i.e. the involvement in the disease of the GM3 ganglioside, a specific glycolipid implicated in muscle cell proliferation and differentiation.


METHODS
qRT-PCR analysis of St3gal5 (GM3 synthase) gene expression and HPLC quantification of GM3 ganglioside were conducted on muscle tissue from a mouse model of HIBM harboring the M712T mutation of GNE (Gne(M712T/M712T) mouse) vs control mice (Gne(+/+) mouse).


RESULTS
St3gal5 mRNA levels were significantly lower in Gne(M712T/M712T) mouse muscles vs Gne(+/+) mouse muscles (64.41%+/-10% of Gne(+/+) levels). GM3 ganglioside levels showed also a significant decrease in Gne(M712T/M712T) mouse muscle compared to Gne(+/+) mouse muscle (18.09%+/-5.33% of Gne(+/+) levels). Although these Gne(M712T/M712T) mice were described to suffer severe glomerular proteinuria, no GM3 alterations were noted in kidneys, highlighting a tissue specific alteration of gangliosides.


CONCLUSIONS
The M712T mutation of GNE hampers the muscle ability to synthesize normal levels of GM3. This is the first time that a mutation of GNE can be related to the molecular pathological mechanism of HIBM.
Paccalet
Thomas
T
Centre de Recherche du Centre Hospitalier Universitaire de Québec-Unité de Génétique Humaine, Université Laval, Québec, Canada.
Coulombe
Zoé
Z
Tremblay
Jacques P
JP
D000818:Animals; D015415:Biomarkers; D002238:Carbohydrate Epimerases / Q000235:genetics; D004195:Disease Models, Animal; D005679:G(M3) Ganglioside / Q000032:analysis* / Q000096:biosynthesis; D051379:Mice; D009097:Multienzyme Complexes / Q000235:genetics*; D018482:Muscle, Skeletal / Q000737:chemistry; D020125:Mutation, Missense; D018979:Myositis, Inclusion Body / Q000209:etiology / Q000235:genetics / Q000378:metabolism*; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis; D012799:Sialyltransferases / Q000032:analysis / Q000235:genetics
D015415:Biomarkers; D005679:G(M3) Ganglioside; D009097:Multienzyme Complexes; D012333:RNA, Messenger; C482901:UDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinase; D012799:Sialyltransferases; C021343:haematoside synthetase; D017853:Phosphotransferases (Alcohol Group Acceptor); C018765:N-acylmannosamine kinase; D002238:Carbohydrate Epimerases; C100033:UDP acetylglucosamine-2-epimerase
Acta Neuropathol. 2001 Jun;101(6):579-84
11515786
Mol Cell Biochem. 1988 Sep;83(1):47-54
3221840
Hum Mol Genet. 2007 Nov 15;16(22):2669-82
17704511
Neurology. 2007 Aug 14;69(7):655-9
17698786
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5267-70
11929971
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3445-9
12629211
Neurology. 2006 Mar 14;66(5):755-8
16534119
Biotechniques. 2005 Feb;38(2):287-93
15727135
J Biol Chem. 2006 Sep 15;281(37):27016-28
16847058
IUBMB Life. 2005 Jul;57(7):477-82
16081368
PLoS One. 2008 Jun 18;3(6):e2477
18560563
Science. 1969 Jun 27;164(3887):1519-21
5786643
Mol Genet Metab. 2004 Mar;81(3):196-202
14972325
Mol Cell Biochem. 1990 Aug 10;96(2):163-73
2274049
Am J Physiol. 1991 Mar;260(3 Pt 2):F291-302
2000947
Cell Mol Life Sci. 2008 Nov;65(23):3725-36
18668202
Cell Death Differ. 2007 Nov;14(11):1916-24
17673919
Biochim Biophys Acta. 1980 Jan 18;617(1):97-109
7353026
Muscle Nerve. 2000 Nov;23(11):1686-93
11054746
Life Sci. 2003 Mar 14;72(17):1997-2006
12597998
Eur J Biochem. 2001 Aug;268(16):4553-61
11502217
Nat Genet. 2000 Jun;25(2):166-72
10835630
J Neurochem. 2008 May;105(3):971-81
18182043
J Biol Chem. 2008 Dec 26;283(52):36265-71
18945680
Anal Biochem. 2004 Aug 15;331(2):275-82
15265733
Glycoconj J. 1995 Oct;12(5):721-8
8595265
Acta Neuropathol. 1998 Jun;95(6):571-5
9650748
Skeletal Radiol. 2008 Jan;37(1):43-8
17962939
FEBS Lett. 2006 Dec 11;580(28-29):6649-54
17118363
Glycobiology. 2005 Nov;15(11):1102-10
15987957
J Neurol Sci. 1984 Apr;64(1):33-43
6737002
J Clin Invest. 2007 Jun;117(6):1585-94
17549255
FASEB J. 2006 Jun;20(8):1248-50
16636105
Am J Pathol. 1996 Sep;149(3):1009-15
8780404
FASEB J. 1997 Mar;11(4):248-55
9068613
J Clin Endocrinol Metab. 2008 Mar;93(3):845-51
18089699
J Biol Chem. 1997 Sep 26;272(39):24313-8
9305887
Glycobiology. 2003 Jun;13(6):487-95
12626401
Biochem Biophys Res Commun. 2005 Mar 4;328(1):221-6
15670773
Curr Opin Neurol. 1999 Oct;12(5):493-9
10590885
J Biochem. 1994 Feb;115(2):248-56
8206874
J Biol Chem. 2004 Mar 19;279(12):11402-7
14707127
Biochemistry. 2006 Mar 7;45(9):2968-77
16503651
Neuromuscul Disord. 2005 Feb;15(2):177-84
15694140
Nat Genet. 2001 Sep;29(1):83-7
11528398
Anal Biochem. 1985 Apr;146(1):220-31
3993932
Glycobiology. 2006 Jan;16(1):1R-27R
16014749
FEBS Lett. 2004 May 21;566(1-3):105-9
15147877
Physiol Genomics. 2008 Sep 17;35(1):106-15
18628337
Neuromuscul Disord. 1998 Jun;8(5):333-7
9673988
J Neurol Sci. 1981 Jul;51(1):141-55
7252518
Glycoconj J. 1994 Oct;11(5):477-85
7696850
Autophagy. 2007 Jul-Aug;3(4):396-8
17471014
Nutr Rev. 2007 Jun;65(6 Pt 2):S39-46
17605313
Cell Prolif. 2005 Dec;38(6):423-33
16300654
Glycoconj J. 1997 Jan;14(1):19-28
9076510
Glycobiology. 1993 Apr;3(2):97-130
8490246
Brain. 1993 Feb;116 ( Pt 1):217-32
8453459
Exp Cell Res. 2005 Apr 1;304(2):365-79
15748884
Hum Mol Genet. 1996 Jan;5(1):159-163
8789455
Glycoconj J. 2007 Apr;24(2-3):125-30
17235685
Mol Cell Biochem. 1994 Jan 26;130(2):173-85
8028596